Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Pipeline Review, H1 2016

  • ID: 3753871
  • Report
  • 33 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • Sphaera Pharma Pvt. Ltd.
  • Toray Industries, Inc.
  • MORE
Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Pipeline Review, H1 2016

Summary

‘Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Pipeline Review, H1 2016’, provides in depth analysis on Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) targeted pipeline therapeutics.

The report provides comprehensive information on the Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10)
- The report reviews Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) targeted therapeutics and enlists all their major and minor projects
- The report assesses Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • Sphaera Pharma Pvt. Ltd.
  • Toray Industries, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) Overview

Therapeutics Development

Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Products under Development by Stage of Development

Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Products under Development by Therapy Area

Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Products under Development by Indication

Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Products under Development by Companies

Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Companies Involved in Therapeutics Development

GlaxoSmithKline Plc

Sphaera Pharma Pvt. Ltd.

Sumitomo Dainippon Pharma Co., Ltd.

Toray Industries, Inc.

Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Drug Profiles

(diclofenac sodium + triclocarban) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EC-5026 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2256294 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Soluble Epoxide Hydrolase for Renal Protection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Soluble Epoxide Hydrolase for Chronic Kidney Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Soluble Epoxide Hydrolase for Myocardial Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Dormant Projects

Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Featured News & Press Releases

Aug 19, 2013: Sphaera Pharma completes phase I trials for neuropathic pain drug

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by GlaxoSmithKline Plc, H1 2016

Pipeline by Sphaera Pharma Pvt. Ltd., H1 2016

Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016

Pipeline by Toray Industries, Inc., H1 2016

Dormant Projects, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
GlaxoSmithKline Plc
Sphaera Pharma Pvt. Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
Toray Industries, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll